Dipartimento Neuroalgologia Centro Cefalee, Fondazione IRCCS Istituto Neurologico C.Besta, Milan, Italy.
University of Milano-Bicocca, Milan, Italy.
Neurol Sci. 2022 Mar;43(3):1583-1585. doi: 10.1007/s10072-021-05836-5. Epub 2021 Dec 21.
The study had been initiated because of restrictions put in place to control the spread of coronavirus in Milan in March 2020 that impacted clinical activities at our tertiary headache center in Milan (Foundation IRCSS Carlo Besta Neurological Institute). Treatment efforts were modified to make use of telephonic and internet communication to maintain care of our patients.
Nineteen patients had undergone our withdrawal protocol for medication overuse headache and were scheduled for follow-up that included pharmacological prophylaxis combined with behavioral therapy and mindfulness, generally performed in small group face-to-face sessions. A behavioral program was organized for them by technology modality (smartphone) due to the pandemic restrictions.
The results concern 12-month follow-up. The clinical indexes showed migraine days per month 20.6 (± 6) pre vs 11.2 (± 3.1 at 12 months); medications intake per month 19.4 (± 5.8) pre vs 9.0 (± 4.6) at 12 months; MIDAS 67.7 (± 52.6) pre vs 71.1 (± 60) at 12 months; HIT-6 66.2 (± 5.3) pre vs 62.2 (± 5.9).
The present study confirmed literature data, supporting the behavioral approach combined to traditional therapies as a novel method to follow patients and guarantee their benefit, also when applied using technology by telemedicine or smartphone.
本研究是由于 2020 年 3 月为控制冠状病毒在米兰的传播而实施的限制措施而发起的，这些措施影响了我们在米兰的三级头痛中心（IRCSS 基金会 Carlo Besta 神经学研究所）的临床活动。治疗工作进行了修改，利用电话和互联网通讯来维持对患者的护理。
19 名患者已经接受了我们的药物过度使用性头痛退出方案，并计划进行随访，其中包括药物预防治疗，结合行为疗法和正念，通常在小团体面对面会议中进行。由于大流行限制，我们通过技术模式（智能手机）为他们组织了一个行为计划。
结果涉及 12 个月的随访。临床指标显示偏头痛天数每月 20.6（±6），治疗前 vs 12 个月时 11.2（±3.1）；每月药物摄入量 19.4（±5.8），治疗前 vs 12 个月时 9.0（±4.6）；MIDAS 67.7（±52.6），治疗前 vs 12 个月时 71.1（±60）；HIT-6 66.2（±5.3），治疗前 vs 12 个月时 62.2（±5.9）。
本研究证实了文献数据，支持将行为方法与传统疗法相结合作为一种新方法来随访患者并保证其获益，即使在使用远程医疗或智能手机等技术时也是如此。
